Literature DB >> 23716537

CD30 expression in peripheral T-cell lymphomas.

Elena Sabattini, Marco Pizzi, Valentina Tabanelli, Pamela Baldin, Carlo Sagramoso Sacchetti, Claudio Agostinelli, Pier Luigi Zinzani, Stefano A Pileri.   

Abstract

Entities:  

Keywords:  angioimmunoblastic T-cell lymphoma; enteropathy associated T-cell lymphoma; extranodal NK/T-cell lymphoma; nasal type

Mesh：

Substances：

Year:  2013        PMID： 23716537      PMCID： PMC3729886          DOI： 10.3324/haematol.2013.084913

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score.

Authors:  Philip Went; Claudio Agostinelli; Andrea Gallamini; Pier Paolo Piccaluga; Stefano Ascani; Elena Sabattini; Francesco Bacci; Brunangelo Falini; Teresio Motta; Marco Paulli; Tullio Artusi; Milena Piccioli; Pier Luigi Zinzani; Stefano A Pileri
Journal:  J Clin Oncol       Date:  2006-04-24       Impact factor: 44.544

2.  The expression of CXCR3 and CD30 in mycosis fungoides.

Authors:  Azita Nikoo
Journal:  Arch Iran Med       Date:  2012-03       Impact factor: 1.354

3.  Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ, γδ, and αβ/γδ T-cell origin: a comprehensive clinicopathologic and phenotypic study.

Authors:  Tawatchai Pongpruttipan; Sanya Sukpanichnant; Thamathorn Assanasen; Pongsak Wannakrairot; Paisarn Boonsakan; Wasana Kanoksil; Kanita Kayasut; Winyou Mitarnun; Archrob Khuhapinant; Udomsak Bunworasate; Teeraya Puavilai; Anan Bedavanija; Adriana Garcia-Herrera; Elias Campo; James R Cook; John Choi; Steven H Swerdlow
Journal:  Am J Surg Pathol       Date:  2012-04       Impact factor: 6.394

4.  Antigen retrieval techniques in immunohistochemistry: comparison of different methods.

Authors:  S A Pileri; G Roncador; C Ceccarelli; M Piccioli; A Briskomatis; E Sabattini; S Ascani; D Santini; P P Piccaluga; O Leone; S Damiani; C Ercolessi; F Sandri; F Pieri; L Leoncini; B Falini
Journal:  J Pathol       Date:  1997-09       Impact factor: 7.996

Review 5.  CD30 in normal and neoplastic cells.

Authors:  R Chiarle; A Podda; G Prolla; J Gong; G J Thorbecke; G Inghirami
Journal:  Clin Immunol       Date:  1999-02       Impact factor: 3.969

6.  An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.

Authors:  P L Tazzari; D de Totero; A Bolognesi; N Testoni; S Pileri; S Roncella; G Reato; H Stein; M Gobbi; F Stirpe
Journal:  Haematologica       Date:  1999-11       Impact factor: 9.941

7.  Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center.

Authors:  Adam Gibb; Craig Jones; Adrian Bloor; Samar Kulkarni; Tim Illidge; Kim Linton; John Radford
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

8.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.

Authors:  H Stein; D Y Mason; J Gerdes; N O'Connor; J Wainscoat; G Pallesen; K Gatter; B Falini; G Delsol; H Lemke
Journal:  Blood       Date:  1985-10       Impact factor: 22.113

9.  Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin.

Authors:  B Falini; A Bolognesi; L Flenghi; P L Tazzari; M K Broe; H Stein; H Dürkop; F Aversa; P Corneli; G Pizzolo
Journal:  Lancet       Date:  1992-05-16       Impact factor: 79.321

10.  Distinct motifs in the intracellular domain of human CD30 differentially activate canonical and alternative transcription factor NF-κB signaling.

Authors:  Sarah L Buchan; Aymen Al-Shamkhani
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240
View more
  30 in total

1.  CD30-positive malignant lymphomas: time for a change of management?

Authors:  Andreas Engert
Journal:  Haematologica       Date:  2013-08       Impact factor: 9.941

Review 2.  Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).

Authors:  Bradley M Haverkos; Carrie Coleman; Alejandro A Gru; Zenggang Pan; Jonathan Brammer; Rosemary Rochford; Anjali Mishra; Christopher C Oakes; Robert A Baiocchi; Aharon G Freud; Pierluigi Porcu
Journal:  Discov Med       Date:  2017-03       Impact factor: 2.970

Review 3.  Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.

Authors:  Lauren Shea; Neha Mehta-Shah
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

Review 4.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 5.  Molecular genetics of peripheral T-cell lymphomas.

Authors:  Pier Paolo Piccaluga; Valentina Tabanelli; Stefano A Pileri
Journal:  Int J Hematol       Date:  2014-01-31       Impact factor: 2.490

Review 6.  Targeted based therapy in nodal T-cell lymphomas.

Authors:  Dai Chihara; Milos Miljkovic; Swaminathan P Iyer; Francisco Vega
Journal:  Leukemia       Date:  2021-03-04       Impact factor: 11.528

Review 7.  Therapeutic Options for Aggressive T-Cell Lymphomas.

Authors:  Jennifer K Lue; Anna Kress; Jennifer E Amengual
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

Review 8.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

9.  Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients.

Authors:  Mathilde Lamarque; Céline Bossard; Adrien Contejean; Pauline Brice; Marie Parrens; Steven Le Gouill; Josette Brière; Reda Bouabdallah; Danielle Canioni; Hervé Tilly; Brigitte Bouchindhomme; Emmanuel Bachy; Richard Delarue; Corinne Haioun; Philippe Gaulard
Journal:  Haematologica       Date:  2015-12-24       Impact factor: 9.941

10.  Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Authors:  Steven Horwitz; Owen A O'Connor; Barbara Pro; Tim Illidge; Michelle Fanale; Ranjana Advani; Nancy L Bartlett; Jacob Haaber Christensen; Franck Morschhauser; Eva Domingo-Domenech; Giuseppe Rossi; Won Seog Kim; Tatyana Feldman; Anne Lennard; David Belada; Árpád Illés; Kensei Tobinai; Kunihiro Tsukasaki; Su-Peng Yeh; Andrei Shustov; Andreas Hüttmann; Kerry J Savage; Sam Yuen; Swaminathan Iyer; Pier Luigi Zinzani; Zhaowei Hua; Meredith Little; Shangbang Rao; Joseph Woolery; Thomas Manley; Lorenz Trümper
Journal:  Lancet       Date:  2018-12-04       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.